Country Access Report
Morocco maintains a strict national control regime that criminalises possession, use, cultivation and trafficking of most classic psychedelics and psychotropic substances, while permitting medical use of certain controlled anesthetic agents (notably ketamine) within hospitals and clinical practice. There is no publicly documented national regulatory approval or reimbursed pathway for psychedelic-assisted therapies (psilocybin, MDMA, etc.); access is therefore effectively limited to approved medical practice for licensed drugs (e.g., ketamine as an anesthetic) or to authorised clinical research where applicable.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled psychotropic/hallucinogenic substance under Moroccan drug control law and related decrees; there is no authorised medical psilocybin program or reimbursement pathway outside of approved clinical research. This classification follows the national schedules and government lists that group psilocybin/psilocin with hallucinogens prohibited for general use. [1] [2]
Compound Access
Currently classified as a strictly controlled substance (listed among hallucinogens/psychotropic substances in Moroccan scheduling instruments) with no authorised medical MDMA-assisted therapy program and no public reimbursement; access is limited to approved clinical research if and when specific research approvals are granted. [1] [2]
Compound Access
There is no public record of a national regulatory approval or reimbursement pathway for esketamine (Spravato) as a marketed, reimbursed antidepressant in Morocco; esketamine would therefore not be available through routine public insurance reimbursement and could only be accessed via authorised clinical trials or compassionate/individual import procedures where permitted by Moroccan authorities. Ketamine (the racemate) is used clinically in Moroccan hospitals as an anaesthetic and in acute/anaesthesia settings, but that established medical use does not imply national marketing authorisation or reimbursement for an esketamine nasal-spray product. For ketamine hospital use see clinical practice and hospital reviews from Moroccan centres. [1] [2] [3]
Compound Access
Ketamine (racemic ketamine) is an established anesthetic and analgesic used in Moroccan hospitals and emergency/anaesthesia practice; it is part of routine hospital formularies for induction, procedural sedation and for certain refractory status epilepticus or intensive‑care indications, and therefore is available in medical settings (public and private hospitals) though not as a reimbursed psychedelic therapy product. Clinical literature and hospital audits from Morocco document ketamine’s availability and clinical use in operating rooms, paediatric burn care, and refractory status epilepticus management in tertiary centres. [1] [2]
Regulatory/coverage context: Moroccan narcotics/psychotropic control law regulates distribution and prescription of controlled substances; ketamine is therefore dispensed and used under clinician prescription and institutional pharmacy controls, not via a specific reimbursed psychedelic‑therapy benefit. There is no published national reimbursement pathway for ketamine when used as an off‑label psychiatric intervention (e.g., for treatment‑resistant depression) and such use would generally be provided at institutional/private clinician discretion without a structured public reimbursement programme. [3]
Regional/state nuance: Morocco’s health system centralises drug regulation at national level; there are no subnational reimbursement programmes analogous to state‑level coverage seen in some federal countries — access/practice differences largely reflect hospital formularies (public vs private) and clinician practice rather than separate regional reimbursement policies.
Compound Access
Compound Access
Compound Access
Currently classified as a strictly controlled substance under Moroccan drug control frameworks with no authorised medical use or reimbursement pathway; access would be limited to approved clinical research only. Morocco’s narcotics laws criminalise possession and unauthorised supply of psychotropic/hallucinogenic substances. [1] [2]
Compound Access
The primary active constituents of ayahuasca (DMT and MAO‑inhibiting plant compounds) fall under the controlled psychotropic drug framework; there is no legal, reimbursed medical pathway for ayahuasca ceremonies or therapeutic use in Morocco, and possession or preparation would be treated under general prohibitions on controlled psychotropic substances except where an authorised clinical research protocol is in place. [1] [2]
Compound Access
Compound Access
The 2C family and related synthetic psychedelic compounds are expressly listed among controlled hallucinogens in Moroccan scheduling instruments and are illegal for non‑authorised purposes; there is no authorised medical use or reimbursement pathway and access is limited to approved clinical research only. [1] [2]
Last updated 2 Mar 2026. Source links come from the medical access guide.